Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase IIa, Multicentre, Randomized, Double-blind, Placebo-controlled, Study to Evaluate the Safety, Tolerability and Efficacy of Treatment With BI 655130 in Adult Patients With Moderate to Severe Atopic Dermatitis

NCT03822832 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT03822832
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03822832 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase IIa, Multicentre, Randomized, Double-blind, Placebo-controlled, Study to Evaluate the Safety, Tolerability and Efficacy of Treatment With BI 655130 in Adult Patients With Moderate to Severe Atopic Dermatitis
Lead sponsor
Boehringer Ingelheim
Phase
Phase 2
Overall status
Completed
Start date
February 12, 2019
Completion date
July 22, 2020
Enrollment
51 (actual)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

dermatitis, atopic